TrialBMJ open2016

Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study.

Isla S Mackenzie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.